Clinical Trial Update: Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravesical rAd-IFN/Syn3 for BCG-refractory or relapsed bladder cancer has completed and posted results. The sponsor is FKD Therapies …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• rAd-IFN/Syn3

Snippet

Sponsor: FKD Therapies Oy | Conditions: Superficial Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-05-30